Oriham Capsule 10 mg

Oriham Capsule 10 mg Uses, Dosage, Side Effects, Food Interaction and all others data.

Oriham Capsule 10 mg
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Oriham Capsule 10 mg
Generic	Atomoxetine Hydrochloride
Weight	10 mg
Type	Capsule
Therapeutic Class	CNS stimulant drugs
Manufacturer	Incepta Pharmaceuticals Ltd.
Available Country	Bangladesh
Last Updated:	October 19, 2023 at 6:27 am

Uses

Attention deficit hyperactivity disorder (ADHD).

Dosage

Oriham Capsule 10 mg dosage

Adult & adolescents->70 kg: Initially: 40 mg/day for at least 7 days. Maintenance: 80 mg/day. Max: 100 mg/day. Children & adolescents-Up to 70 kg: Initially: 0.5 mg/kg/day for at least 7 days. Maintenance: 1.2 mg/kg/day. Max: 1.8 mg/kg/day.

Side Effects

Decreased appetite; headache; nausea; increased BP & heart rate; Insomnia; dry mouth in adults; Somnolence; abdominal pain; vomiting in children.

Precaution

Atomoxetine should be used with caution in patients with a history of seizures. Atomoxetine can affect heart rate and blood pressure. It is recommended that the heart rate and blood pressure be measured before treatment is started and periodically during treatment to detect possible clinically important increases. Most patients taking Atomoxetine experience a modest increase in heart rate

Interaction

Albuterol, CYP2D6 inhibitors & antihypertensive agents interact with Atomoxetine.

Pregnancy & Breastfeeding use

Pregnancy Category C. Either studies in animals have revealed adverse effects on the fetus (teratogenic or embryocidal or other) and there are no studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the fetus.

Contraindication

Hypersensitivity to Atomoxetine Concomitant use with Monoamine oxidase inhibitors (MAOIs). Narrow-angle glaucoma. Severe cardiovascular or cerebrovascular disorders. History of pheochromocytoma.

Special Warning

Pediatric use: The pharmacokinetics of Atomoxetine have not been evaluated in children under 6 years of age.

Acute Overdose

The most commonly reported gastrointestinal symptoms including somnolence, dizziness, tremor, and abnormal behaviour. Hyperactivity and agitation have also been reported. Signs and symptoms consistent with mild to moderate sympatheticnervous system activation (e.g. tachycardia, blood pressure increased, mydriasis, dry mouth) were also observed. Most events were mild to moderate. In some cases of overdose involving Atomoxetine, seizures and very rarely QT prolongation have been reported. There is limited clinical trial experience with Atomoxetine overdose. No fatal overdoses occurred in clinical trials.